Alpha Tau Medical to Spotlight Alpha DaRT at Healthcare Conference
Alpha Tau to Present at the Jefferies Global Healthcare Conference
6-K: Report of foreign private issuer (related to financial reporting)
Press Release: Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(TM), reported first quarter 2024 financial results and provided a corporate update.
Express News | Alpha Tau Treats First Patient With Liver Cancer Metastases Treaded In Study Of Alpha DaRT
Express News | Alpha Tau Announces Alpha Dart Treatment of First Patient With Liver Metastases of Colorectal Cancer
Alpha Tau Announces Alpha DaRT Treatment of First Patient With Liver Metastases of Colorectal Cancer
The study primarily aims to examine the feasibility of delivering Alpha DaRT sources into the liver metastases, as well as the safety of utilizing the Alpha DaRT sources in the liver by assessing the frequency and severity of related adverse events.
Express News | Alpha Tau Medical Ltd - Significant Reduction in Distant Pancreatic Cancer Tumor Growth Rate After First Tumor Is Treated With Alpha Dart Alone
Express News | Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at Estro 2024 Congress in Glasgow
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, t
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT,
Buy Rating Affirmed: Anticipating Alpha Tau Medical's Clinical Milestones and Growth Potential in 2024
Express News | HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Alpha Tau Medical Price Target Cut to $7.00/Share From $8.00 by Piper Sandler
Alpha Tau Medical Price Target Cut to $7.00/Share From $8.00 by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Alpha Tau Medical, Lowers Price Target to $7
Alpha Tau Medical Ltd (DRTS) Gets a Buy From Piper Sandler
Alpha Tau Medical GAAP EPS of -$0.42
Press Release: Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT,
Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans